share_log

Compugen | 6-K: Report of foreign private issuer (related to financial reporting)

Compugen | 6-K: Report of foreign private issuer (related to financial reporting)

Compugen医疗 | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/06 19:03

Moomoo AI 已提取核心信息

Compugen reported Q2 2024 financial results, highlighting FDA clearance of COM503 IND which triggered a $30 million milestone payment from Gilead. The company recorded revenues of $6.7 million and reduced net loss to $2.1 million compared to $9.3 million in Q2 2023. Cash position stood at $92.3 million as of June 30, 2024, expected to fund operations into 2027.The company remains on track to present data from COM701 + COM902 + pembrolizumab study in platinum resistant ovarian cancer in Q4 2024. Previous data showed encouraging results with 20% overall response rate and durable responses lasting over 16 months. Additionally, partner AstraZeneca is advancing rilvegostomig development with a projected non-risk-adjusted peak year revenue target exceeding $5 billion.R&D expenses decreased to $6.2 million from $7.8 million year-over-year, while G&A expenses slightly reduced to $2.2 million. The company plans to initiate a Phase 1 trial for COM503 as monotherapy and in combination with zimberelimab in advanced solid tumors in Q4 2024.
Compugen reported Q2 2024 financial results, highlighting FDA clearance of COM503 IND which triggered a $30 million milestone payment from Gilead. The company recorded revenues of $6.7 million and reduced net loss to $2.1 million compared to $9.3 million in Q2 2023. Cash position stood at $92.3 million as of June 30, 2024, expected to fund operations into 2027.The company remains on track to present data from COM701 + COM902 + pembrolizumab study in platinum resistant ovarian cancer in Q4 2024. Previous data showed encouraging results with 20% overall response rate and durable responses lasting over 16 months. Additionally, partner AstraZeneca is advancing rilvegostomig development with a projected non-risk-adjusted peak year revenue target exceeding $5 billion.R&D expenses decreased to $6.2 million from $7.8 million year-over-year, while G&A expenses slightly reduced to $2.2 million. The company plans to initiate a Phase 1 trial for COM503 as monotherapy and in combination with zimberelimab in advanced solid tumors in Q4 2024.
Compugen医疗公布了2024年第二季度财务业绩，强调了COM503 IND获得FDA批准，这触发了来自吉利德的3000万美元里程碑付款。该公司报告营业收入为670万美元，净亏损减少至210万美元，相较于2023年第二季度的930万美元。截止到2024年6月30日，现金状况为9230万美元，预计将支持其运营直到2027年。该公司仍按计划在2024年第四季度展示关于COM701 + COM902 + Pembrolizumab研究在铂金耐药卵巢癌中的数据。之前的数据表明，整体应答率为20%，并且持久反应持续超过16个月。此外，合作伙伴阿斯利康正在推进rilvegostomig的开发，预计非风险调整的峰值年度营业收入目标超过50亿元。研发费用同比减少至620万美元，去年为780万美元，而一般管理费用略微减少至220万美元。该公司计划于2024年第四季度启动COM503的单药和与zimberelimab联合用于晚期实体瘤的第一阶段试验。
Compugen医疗公布了2024年第二季度财务业绩，强调了COM503 IND获得FDA批准，这触发了来自吉利德的3000万美元里程碑付款。该公司报告营业收入为670万美元，净亏损减少至210万美元，相较于2023年第二季度的930万美元。截止到2024年6月30日，现金状况为9230万美元，预计将支持其运营直到2027年。该公司仍按计划在2024年第四季度展示关于COM701 + COM902 + Pembrolizumab研究在铂金耐药卵巢癌中的数据。之前的数据表明，整体应答率为20%，并且持久反应持续超过16个月。此外，合作伙伴阿斯利康正在推进rilvegostomig的开发，预计非风险调整的峰值年度营业收入目标超过50亿元。研发费用同比减少至620万美元，去年为780万美元，而一般管理费用略微减少至220万美元。该公司计划于2024年第四季度启动COM503的单药和与zimberelimab联合用于晚期实体瘤的第一阶段试验。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

独立文件4

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点